MX2017008430A - Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada. - Google Patents

Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada.

Info

Publication number
MX2017008430A
MX2017008430A MX2017008430A MX2017008430A MX2017008430A MX 2017008430 A MX2017008430 A MX 2017008430A MX 2017008430 A MX2017008430 A MX 2017008430A MX 2017008430 A MX2017008430 A MX 2017008430A MX 2017008430 A MX2017008430 A MX 2017008430A
Authority
MX
Mexico
Prior art keywords
methods
fused bicyclic
preparing fused
diaminopyrimidine derivatives
diaminopyrimidine
Prior art date
Application number
MX2017008430A
Other languages
English (en)
Inventor
P Bakale Roger
P Allwein Shawn
E Petrillo Daniel
KLUWER Sander
R Mowrey Dale
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MX2017008430A publication Critical patent/MX2017008430A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente descripción está dirigida a métodos mejorados útiles para la preparación de, por ejemplo, 2-[[5-cloro-2-[[(6S)-6-[4-(2- hidroxietil)piperazina-1-il]-1-metoxi-6,7,8,9-tetrahidro-5Hbenzo[ 7]anuleno-2-il]amino]-irimidina-4-il]amino]-N-metil-benzamida (CEP-37440).
MX2017008430A 2014-12-23 2015-12-23 Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada. MX2017008430A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462095861P 2014-12-23 2014-12-23
PCT/US2015/000301 WO2016105529A1 (en) 2014-12-23 2015-12-23 Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives

Publications (1)

Publication Number Publication Date
MX2017008430A true MX2017008430A (es) 2018-03-23

Family

ID=55221488

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008430A MX2017008430A (es) 2014-12-23 2015-12-23 Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada.

Country Status (9)

Country Link
US (1) US10259794B2 (es)
EP (1) EP3237408B1 (es)
JP (1) JP6849594B2 (es)
CA (1) CA2971415A1 (es)
ES (1) ES2707123T3 (es)
HK (1) HK1244789B (es)
IL (1) IL252945B (es)
MX (1) MX2017008430A (es)
WO (1) WO2016105529A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2865420C (en) * 2012-03-06 2020-06-02 Cephalon, Inc. Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
JP6433974B2 (ja) 2013-03-14 2018-12-05 トレロ ファーマシューティカルズ， インコーポレイテッド Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
WO2020023910A1 (en) 2018-07-26 2020-01-30 Tolero Pharmaceuticals, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01149775A (ja) * 1987-12-07 1989-06-12 Kawaken Fine Chem Co Ltd 光学活性２−メチルピペラジンの製造方法
MX2009011787A (es) * 2007-05-03 2009-11-13 Cephalon Inc Procesos para preparar (r)-2-metilpirrolidina y (s)-2-metilpirrolidina y sales de tartrato de las mismas.
EP2062906A1 (en) 2007-11-22 2009-05-27 Universiteit van Amsterdam Coordination complex system comprising tautomeric ligands
CA2865420C (en) 2012-03-06 2020-06-02 Cephalon, Inc. Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor

Also Published As

Publication number Publication date
CA2971415A1 (en) 2016-06-30
JP2018507173A (ja) 2018-03-15
IL252945B (en) 2020-05-31
WO2016105529A1 (en) 2016-06-30
EP3237408A1 (en) 2017-11-01
US10259794B2 (en) 2019-04-16
EP3237408B1 (en) 2018-10-31
ES2707123T3 (es) 2019-04-02
IL252945A0 (en) 2017-08-31
US20170369451A1 (en) 2017-12-28
HK1244789B (en) 2019-12-06
JP6849594B2 (ja) 2021-03-24

Similar Documents

Publication Publication Date Title
PH12020550703A1 (en) Sulfonamide compounds and use thereof
IL279910A (en) Crystal forms of 5-chloro-ene 4-[2-(dimethylphosphoryl)phenyl]-ene 2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidin-2- 4-diamine
NZ630251A (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
PH12018501643A1 (en) Tlr7 agonist crystalline form a, preparation method and use thereof
WO2017108723A3 (en) PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
PH12016502523A1 (en) Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
EA201690303A1 (ru) ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНОВ ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ
NZ727996A (en) Thieno [3,2-d] pyrimidine, furo [3,2,d] pyrimidine, and pyrrolo [3,2-d] pyrimidines useful for treating respiratory syncytial virus infections
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
SA518400333B1 (ar) شكل متعدد الأشكال من n- {6-(2-هيدروكسي بروبان-2-يل) -2-[2-(مثيل سلفونيل) إثيل]-2h-إندازول-5-يل}-6-(ثلاثي فلورومثيل) بيريدين-2-كربوكساميد
NZ722624A (en) Fused pyrimidines as inhibitors of p97 complex
PH12015501363B1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
ZA201805240B (en) Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses
JOP20150179B1 (ar) مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
EP4606784A3 (en) Co-crystals, salts and solid forms of tenofovir alafenamide
JOP20150177B1 (ar) مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
PH12018502246A1 (en) Substituted fused pyrimidinone compounds
IL252945A0 (en) Methods for the preparation of fused cyclic derivatives of 4,2-diaminopyrimidine
TWD176852S (zh) 化粧品用座台
TWD175704S (zh) 化粧瓶用補充用容器

Legal Events

Date Code Title Description
FG Grant or registration